INCIDENCE OF BCR‐ABL MUTATIONS IN CML AND OUTCOMES OF PATIENTS WHO FAILED TYROSINE.
To assess the incidence of BCR-ABL kinase domain (KD) mutation detection and its prognostic significance in chronic phase chronic myeloid leukemia (CP-CML) patients treated with tyrosine kinase inhibitors (TKIs). We analyzed characteristics and outcome of 253 CP-CML patients who had at least one mutation analysis performed using direct sequencing. Of them, 187 patients were early […]
INCIDENCE OF BCR‐ABL MUTATIONS IN CML AND OUTCOMES OF PATIENTS WHO FAILED TYROSINE. Read More »
